2022 in facts and figures
2022 was a year of acceleration and progress for Pierre Fabre Laboratories, marked by the end of the Transformation Plan launched in 2019 and the completion of many initiatives.
February
1,000th Group patent, granted for the use of Milk Thistle in the XeraCalm range, marketed by the Eau Thermale Avène brand to relieve dry skin and itching.
June
Launch of the Vik CRC mobile app, developed in collaboration with Spain’s patient association EuropaColon to help colorectal cancer patients and their families find answers to their questions.
July
A pop-up village open to the public created in Castres to celebrate the Group’s.
Conclusion of an exclusive licensing agreement in urology with Urovant, allowing the Pierre Fabre group to register and market products in Europe.
August
Acquisition of a stake in Gennisium Pharma, an innovative French company specializing in niche prescription drugs for premature babies.
Birth of the first baby treated in the EDELIFE clinical trial for prenatal treatment of X-linked hypohidrotic ectodermal dysplasia (XLHED), an orphan pediatric and genetic disease.
September
Launch of the Eczema CARE mobile app (formerly PO-Scorad) by the Pierre Fabre Eczema Foundation, developed by its expert doctors to help better manage the disease.
AFNOR certification obtained for the Pierre Fabre Group’s commitment to corporate social responsibility, and the first major industrial group to receive an “exemplary” score.
November
Visible Diseases of the Skin (VDS), the first international epidemiological study on the prevalence and psychosocial impact of chronic visible dermatoses, involving over participants in 6 countries.
Launch of the Hyaluron Activ B3 range by Eau Thermale Avène, characterized by a new cellular senescence approach to combating signs of aging and a reduced environmental footprint.
December
Marketing authorization for a new targeted therapy through a licensing agreement with Atara Biotherapeutics, for the treatment of adults and children with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
Ranked in the top 3 2022 EPOKA / Harris Interactive ranking (in partnership with l’Étudiant) of favorite companies of students and recent graduates in the pharmaceutical
Announcement of the creation of the Green Impact Index Consortium with 25 stakeholders representing over 1,000 companies under the aegis of the AFNOR standards organization, to develop an environmental and social labeling tool for cosmetics and wellness products.